<DOC>
	<DOC>NCT00931827</DOC>
	<brief_summary>The study examines the use of Mirena or Implanon for long-term contraception in women. The duration of therapy use is the key focus of the study. Also, any reasons for discontinuation and the safety profile will be examined. In addition, patients are asked to fill out a short questionnaire about their menstrual bleeding before and during therapy.</brief_summary>
	<brief_title>Acceptability of Long-term Progestin-only Contraception in Europe</brief_title>
	<detailed_description />
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Etonogestrel</mesh_term>
	<mesh_term>Progestins</mesh_term>
	<criteria>Women aged 2035 in good general health requesting contraception Women who have used shortacting hormonal contraception (combined or progestogenonly pills, vaginal ring or contraceptive patch) for at least 3 cycles immediately before entering the study and opting to change to either Mirena or Implanon for contraception Women who have given a written informed consent to participate in the study (if applicable) The contraindications and warnings of the respective Summary of Product Characteristics (Mirena or Implanon) must be followed. The decision to start Mirena or Implanon has to be made clearly before the decision to include patients in the study Patients who are breastfeeding at time of inclusion for the study will also be excluded since breastfeeding affects the bleeding pattern</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Contraception</keyword>
</DOC>